Journal Article

The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB)

Abel, Mary Kathryn, Rothschild, Harriet T, Khan, Seema A, Mukhtar, Rita A, Chien, A Jo, Clelland, Elle N, Esserman, Laura, Shui, Amy M

2024

Overview

Purpose Primary site surgery for metastatic breast cancer improves local control but does not impact overall survival. Whether histologic subtype influences patient selection for surgery is unknown. Given differences in surgical management between early-stage lobular versus ductal disease, we evaluated the impact of histology on primary site surgery in patients with metastatic breast cancer. Methods The National Cancer Database (NCDB, 2010–2016) was queried for patients with stage IV HR-positive, HER2-negative invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). We compared clinicopathologic features, primary site surgery rates, and outcomes by histologic subtype. Multivariable Cox proportional hazard models with and without propensity score matching were used for overall survival (OS) analyses. Results In 25,294 patients, primary site surgery was slightly but significantly less common in the 6,123 patients with ILC compared to the 19,171 patients with IDC (26.9% versus 28.8%, p  = 0.004). Those with ILC were less likely to receive chemotherapy (41.3% versus 47.4%, p  < 0.0001) or radiotherapy (29.1% versus 37.9%, p <  0.0001), and had shorter OS. While mastectomy rates were similar, those with ILC who underwent lumpectomy had significantly higher positive margin rates (ILC 15.7% versus IDC 11.2%, p =  0.025). In both groups, the odds of undergoing surgery decreased over time, and were higher in younger patients with T2/T3 tumors and higher nodal burden. Conclusion Lobular histology is associated with less primary site surgery, higher positive margin rates, less radiotherapy and chemotherapy, and shorter OS compared to those with HR-positive HER2-negative IDC. These findings support the need for ILC-specific data and treatment approaches in the setting of metastatic disease.

• Publisher: Springer US,Springer,Springer Nature B.V
• Subject: Breast cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - surgery / Cancer / Cancer research / Carcinoma / Carcinoma, Ductal, Breast - drug therapy / Carcinoma, Ductal, Breast - surgery / Carcinoma, Lobular - drug therapy / Carcinoma, Lobular - surgery / Chemotherapy / Comparative analysis / Epidemiology / ErbB-2 protein / Female / Histology / Humans / Invasiveness / Lumpectomy / Mastectomy / Mastectomy, Segmental / Medicine / Medicine & Public Health / Metastases / Metastasis / Oncology / Oncology, Experimental / Patients / Population studies / Population-based studies / Radiation therapy / Radiotherapy / Surgery / Survival